The whole arc — prohibition (1937), Prop 215 and the medical wave (1996→), legalization and the hemp pilot (2012→), the 2018 Farm Bill, the delta-8 and THCA eras, and the §781 endgame. 177 sourced milestones, ending (so far) at the §781 total-THC ban, 93 days out.
Section 781 hemp redefinition becomes effective 365 days after November 12, 2025 enactment; total THC <0.3% dry-weight and <0.4mg per container limits now enforceable; prior delta-9-only standard expires; vast majority of hemp-derived cannabinoid products become federally non-compliant.
Illinois SB 3222, signed June 12 2026, takes effect November 12 2026, redefining hemp to total-THC standard (0.4 mg per container), banning smokable/inhalable hemp, and restricting synthetic cannabinoids including delta-8 and delta-10.
Pennsylvania currently permits THCA hemp products (<0.3% delta-9), but pending state legislation (Senate Committee March 2026) would bar intoxicating hemp-derived THC products; federal total-THC standard takes effect November 12 2026.
North Carolina SB (House version) HB 328, passed by Senate July 2026 but delayed in House until November 2026, would ban all intoxicating hemp products (total THC >0.4 mg) and synthetic kratom, with phased implementation starting July 15 2026.
New Hampshire SB 624, passed July 9 2026 with portions effective January 1 2027, restricts hemp-derived THC to 0.4 mg per container, prohibits sales to anyone under 21, and creates penalties for violators.
DEA hearing on proposed rescheduling of marijuana to Schedule III commences June 29, 2026, following E.O. 14370 directive to expedite process; hearing conducted to build additional administrative record before final rule.
IHC Investments and Bluestar Operations file petitions in 9th and 4th Circuits against DEA/DOJ challenging classification of hemp-derived hexahydrocannabinol (HHC) as synthetic THC under Schedule I, arguing HHC occurs naturally in hemp.
In response to E.O. 14370, DEA terminates all pending hearing proceedings related to the May 21, 2024 NPRM and initiates new hearing schedule effective June 29, 2026 to expedite completion of rescheduling process.
DEA publishes final rule rescheduling FDA-approved medical marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act.
Texas Department of State Health Services rule effective March 31, 2026 redefines hemp compliance testing to include both delta-9 THC and THCA, effectively banning most smokable hemp products; rule challenged in state court.
Texas DSHS adopted a total-THC hemp rule (delta-9 + THCA at 0.3% dry weight) effective March 31 2026, banning most smokable hemp products; rule faced court injunctions and reinstatement via Executive Order GA-56.
SB 56 (signed Dec 19, 2025) banned intoxicating hemp — delta-8/10, THCA, >0.4 mg total THC per container — outside licensed dispensaries effective March 20, 2026.
H.R. 7010 introduced in 119th Congress to extend Section 781 implementation deadline by two years to November 12, 2028, citing industry compliance burden and transition challenges; bill status pending as of August 2026.
New Jersey Governor Murphy signed P.L. 2025 c.215 on January 12 2026, restricting intoxicating hemp-derived products (delta-8, delta-9, delta-10, THCA) to >0.3% THC, with sales transitioning to licensed liquor stores/dispensaries by November 13 2026.
Executive Order 14370 directs Attorney General to complete marijuana rescheduling to Schedule III in most expeditious manner; voids prior December 2024 hearing and triggers new hearing proceedings effective June 29, 2026.
Michigan's Cannabis Regulatory Agency treats hemp-derived THCA products as marijuana, restricting retail sales to licensed dispensaries. Senate passed Bill 28-7 in late 2025 formalizing that intoxicating hemp must route through the licensed system.
President Trump signs FY2026 Agriculture appropriations (P.L. 119-37), which includes Section 781 redefining hemp by total THC concentration (not delta-9 alone) at <0.3% dry-weight basis and limiting final hemp-derived products to 0.4mg THC per container.
Section 781 mandates FDA within 90 days of enactment (P.L. 119-37, Nov 12, 2025) publish lists of naturally occurring cannabinoids, THC class cannabinoids, and known cannabinoids with THC-like effects; also requires defining term 'container' for product limits.
California AB 8, signed by Governor Newsom September 2025 and effective January 1 2026, moves smokable hemp (THCA flower, prerolls) from the unregulated market into the licensed cannabis dispensary system and bans synthetic cannabinoids.
New Mexico Environment Department issued emergency amendment (August 1 2025) banning synthetic cannabinoids (delta-8, delta-10, HHC) in hemp finished products; finalized as permanent rule after December 2 2025 hearing.
Delaware treats all tetrahydrocannabinols (including THCA, delta-8) as Schedule I controlled substances outside the licensed cannabis system under 16 Del. C. § 4714; adult-use retail opened August 1 2025 as sole legal channel for intoxicating products.
Alabama's HB 445 classifies the manufacture, distribution, and sale of smokable hemp (THCA flower, vapes) as a Class C felony with up to 10 years imprisonment, effective July 1 2025, while capping edibles at 10 mg servings.
Maryland SB 214 and HB 12 (effective July 1 2025) empower the Alcohol, Tobacco, and Cannabis Commission to regulate non-cannabis THC products; Appellate Court held (September 9 2025) that intoxicating hemp (THCA, delta-8) is illegal outside licensed dispensaries.
Texas Governor Greg Abbott vetoed SB 3 on June 22 2025, which would have banned hemp-derived THC, citing unconstitutional vagueness and unenforceable legal challenges; instead called a special session to pursue regulations.
Tennessee Public Chapter 526 (HB 1376), signed May 21 2025, transfers hemp-derived cannabinoid oversight from TDA to TABC, reclassifies THCA above 0.3% as marijuana, and defines total THC as THCA×0.877 + delta-9.
West Virginia legislative rule effective May 15 2025 grants Alcohol Beverage Control Administration investigative and permitting authority over hemp and kratom retail, setting age-control and labeling standards.
Utah HB 54, effective May 7 2025, expands the ban on synthetic cannabinoids (delta-8, delta-10, HHC) and reinforces the smokable hemp flower prohibition; products capped at 5 mg THC per serving, 150 mg per package.
Nebraska LB 316 (2025) would ban most consumable hemp by redefining hemp to total-THC standard (0.3%) and capping products at 10 mg per package; stalled in legislature May 2025, carried over to 2026.
Montana SB 375 (2025) bans retail sale of all hemp products containing detectable THC unless FDA-approved, eliminating nearly all intoxicating hemp from the market.
Oklahoma Governor Stitt issued April 21 2025 directive targeting delta-8, delta-10, HHC, THC-O, and THCP enforcement; THCA flower remains legal under 0.3% delta-9 standard, though federal total-THC changes loom November 12 2026.
Montana HB 49, signed April 7 2025, caps hemp products at 0.5 mg delta-9 THC per serving and 2 mg per package, effectively banning most intoxicating hemp beverages and edibles from retail.
Rep. Mary Miller and colleagues introduce H.R. 6209 to repeal Section 781 hemp redefinition provisions and maintain 0.3% delta-9 THC standard; bill reflects industry opposition to November 2026 implementation deadline.
Kansas SB 292 (2025) proposes age-21+ restrictions and labeling requirements for intoxicating hemp; remains in committee. Kansas currently uses 0.3% total-THC standard; vapes, cigarettes, and flower banned at retail.
S. 3686 and H.R. 7024 introduced to provide regulatory certainty and delay hemp definition changes; bills seek to give industry time to transition to Section 781 compliance before November 12, 2026 effective date.
Nevada SB 356 (2025) closes the hemp retail channel for intoxicating products, routing them to cannabis dispensaries with 10 mg servings/100 mg packages; effective 2025, following SB 49 (2021) all-isomer THC definition.
Hawaii Department of Health interim rules (effective December 6 2024) ban gummies, inhalables (flower, vapes), and foods/beverages containing hemp; allow only tablets, capsules, powders, and liquids at ≤1 mg THC per serving; THCA flower prohibited.
Congress enacts second one-year extension covering FY2025 and the 2025 crop year; hemp programs continue under 2018 Farm Bill definitions as Congress debates hemp-related amendments in farm bill proposals.
Connecticut PA 24-76 (HB 5150), signed May 11 2024 and effective October 1 2024, creates a regulated 0.5-5 mg total THC per container hemp tier; sales restricted to cannabis establishments and DCP licensees as of January 1 2025.
California DPH-24-005-E, approved September 23 2024, bans hemp products with detectable total THC per serving, restricts sales to age 21+, and imposes 5-serving-per-package limits on intoxicating hemp edibles and beverages.
Missouri Governor Mike Parson signed Executive Order 24-10 in August 2024, banning the sale of unregulated hemp products containing delta-8, delta-10, and other psychoactive cannabinoids effective September 1 2024, sparking industry litigation.
DEA announces administrative hearing on proposed marijuana rescheduling to commence December 2, 2024 at Arlington facility; participation notice deadline September 30, 2024; hearing addresses public comments on the May 2024 NPRM.
Iowa HF 2605, signed by Governor Reynolds May 17 2024 and effective July 1 2024, caps hemp edibles at 0.3% total THC or 4 mg per serving/10 mg per package, requires state packaging/labeling standards, and prohibits sales to under-21.
Florida Governor DeSantis vetoed SB 1698 on June 7 2024, which would have banned delta-8 THC and imposed strict hemp regulations, citing excessive regulatory burden on small businesses.
H.R. 8467 (House Farm Bill) and H.R. 9027 §760 (FY2025 Ag Appropriations) both propose amending 7 U.S.C. §1639o to include total THC limits and restrict synthetic cannabinoids; neither enacted, foreshadowing December 2025 Section 781.
Louisiana Act 752 (HB 952), signed June 2024 and effective January 1 2025, bans all smokable and inhalable hemp products including THCA flower, prerolls, and vapes at retail, while permitting non-inhalable edibles and tinctures.
Colorado's 2022-2023 hemp legislation banned synthetic cannabinoids (delta-8, delta-10) from manufacture and sale; 2025 regulations set strict potency ratios (25:1 CBD:THC) and caps. Inspection/audit frequency increased Q2 2024 onwards.
Vermont defines acceptable hemp potency at ≤0.3% delta-9 and ≤1.0% total theoretical THC (delta-9 + THCA×0.877) by dry weight; restricts high-THCA hemp products (THCA flower, concentrates) to licensed cannabis dispensaries only.
Arizona's 2024 Attorney General opinion treats intoxicating hemp products (delta-8, THCA flower, HHC) as Schedule I controlled substances outside the cannabis dispensary system, banning retail sales outside licensed channels.
DOJ/DEA publishes NPRM in Federal Register proposing to transfer marijuana from Schedule I to Schedule III consistent with HHS recommendation; public comment period closes July 22, 2024; hearing request deadline June 20, 2024.
Massachusetts Department of Public Health (May 2024) banned hemp-derived CBD and THC from food, beverages, and dietary supplements; THCA flower and concentrates remain available, but hemp edibles face restrictions at point-of-sale.
Georgia's SB 494, signed April 30 2024 and effective October 1 2024, establishes state licensing and testing for hemp manufacturers and retailers while capping products at 0.3% delta-9 THC, with a 21+ age restriction.
Oregon HB 4121 (March 2024) and HB 3825 (2025) ban artificially derived cannabinoids (delta-8, delta-10, CBN) from hemp; HB 4121 limits edibles to 2 mg THC/serving, 20 mg/container. Hemp retailers require ODA licenses (July 1 2024) and OLCC Hemp Registry (January 1 2026).
Mississippi HB 1676 (2024) proposes state testing and approval for intoxicating hemp products including THCA, delta-8, and delta-10; defines total THC including THCA conversion. Status pending in legislature.
Minnesota's Office of Cannabis Management applies post-decarboxylation total-THC testing to hemp (delta-9 + THCA×0.877), effectively banning THCA flower at hemp retail; smokable cannabis only legal through licensed dispensaries.
South Carolina HB 4628 (2024) would establish state licensing and testing for hemp-derived cannabinoid products (delta-8, delta-10, THCA) with age 21+ restrictions and packaging requirements; referred to committee, status pending.
Kentucky's 302 KAR 50:070 bans retail hemp flower sales; THCA products (vapes, edibles, tinctures) must be registered and capped at 0.3% total THC calculated post-decarboxylation; out-of-state manufacturers must register annually.
P.L. 118-22, Division B, §102 extends 2018 Farm Bill programs for one additional year covering 2024; hemp provisions continue under existing 0.3% delta-9 THC standard pending comprehensive farm bill reauthorization.
HHS submits scientific and medical evaluation to DEA recommending marijuana be transferred from Schedule I to Schedule III, citing evidence of accepted medical use in treating pain, chemotherapy nausea, and anorexia; over 30,000 practitioners authorized to recommend it.
Virginia's SB 903 established a strict total-THC standard (delta-9 + 87% THCA) capped at 0.3% by dry weight and 2 mg per retail package, creating the first state-level total-THC hemp definition that federal courts upheld as not preempted by the 2018 Farm Bill.
Washington SB 5367 (2023) reclassifies hemp products with >0.3% total THC as cannabis, restricting THCA flower, delta-8 edibles, and hemp-derived delta-9 to licensed cannabis retailers only; WSLCB enforcement ongoing through 2024-2025.
Arkansas Act 629 classifies intoxicating cannabinoids (delta-8, delta-10, synthetics) as Schedule VI controlled substances and bans hemp-derived products that convert to delta-9 THC, including THCA flower and concentrates.
Governor Andy Beshear issued executive order November 15, 2022 declaring delta-8 is not a controlled substance under Kentucky law or federal law, overturning state Department of Agriculture's 2021 ban after Hemp Association court victory.
North Carolina passed permanent legislation SL 2022-32 on June 30, 2022 declassifying hemp as controlled substance and exempting tetrahydrocannabinols in hemp products containing <0.3% delta-9 THC on dry weight basis.
Minnesota House File 4065 signed into law June 2022 established legal framework for hemp-derived edibles and beverages limited to 5mg THC per serving, 50mg per container, effectively restricting high-potency delta-8 products.
Colorado SB 22-205 passed May 31, 2022 prohibiting chemical conversion of hemp to delta-8 and other cannabinoids, establishing task force to regulate intoxicating hemp. Codified restrictions on artificial cannabinoids.
U.S. Court of Appeals for the Ninth Circuit holds that the plain text of the 2018 Farm Bill legalizes delta-8 THC products derived from hemp meeting the 0.3% delta-9 THC threshold, affirming trademark protection for AK Futures' delta-8 products.
Pennsylvania Senators Sharif Street and Judith L. Schwank issued April 2022 memorandum describing intent to introduce legislation banning delta-8 THC, though smokable hemp remained legally available in private spaces.
Arizona Senate passed SB 1715 in March 2022 to make manufacturing and sales of delta-8 THC a felony. State's industrial hemp law notably excluded hemp extracts and derivatives from protected definition.
Following 2022 AK Futures ruling, hemp-derived cannabinoid products (delta-8, delta-10, THC-O, HHC) proliferate nationwide; products marketed in formats mimicking snack brands; FDA and health agencies issue warnings about safety and potency.
Illinois Department of Agriculture issued 2022 notice banning synthetic processing of hemp-derived delta-8 THC in the state, though no legislation was formally passed to codify the prohibition.
Rhode Island classified delta-8 THC as Schedule I controlled substance under Uniform Controlled Substances Act around 2022, fully prohibiting hemp-based intoxicants despite earlier hemp legalization.
Virginia Department of Agriculture and Consumer Services began regulating industrial hemp production January 1, 2022 using post-decarboxylation delta-9 THC testing (total delta-9 THC), limiting hemp crops to 0.3% THC concentration.
Maine passed LD 1942 during 2021-2022 period to transition hemp program from 2014 Farm Bill authority to 2018 Farm Bill compliance. Delta-8 remained legal; state maintained unregulated hemp-based intoxicants framework.
USDA delays enforcement of requirement that all hemp testing must be performed by DEA-registered laboratories due to inadequate testing capacity; deadline extended from January 1, 2023 to December 31, 2023, later extended further to December 2025.
New York Cannabis Control Board approved final cannabinoid hemp regulations in November 2021 explicitly prohibiting delta-8 THC and smokable hemp products, with temporary ban implemented May 2021 made permanent.
Governor Gavin Newsom signed AB 45 permitting manufacture and sale of hemp-derived products including CBD in food, beverages, supplements, and cosmetics with <0.3% THC, with mandatory lab testing and labeling requirements.
South Carolina Attorney General Alan Wilson issued advisory opinion October 4, 2021 stating delta-8 and other THC isomers are not protected under Hemp Farming Act, creating uncertainty around product legality though opinion was not binding on courts.
Governor Mike Dunleavy signed SB 27 in September 2021 creating permanent hemp pilot program compliant with 2018 Farm Bill. State law does not exempt hemp-derived delta-8 from controlled substances classification.
DEA releases opinion letter clarifying delta-8 THC extracted from hemp (delta-9 THC <0.3%) is hemp-derived and not controlled, but delta-8 THC synthesized from non-cannabis materials is synthetic THC and Schedule I controlled substance.
Governor Kate Brown signed HB 3000 giving Oregon Liquor and Cannabis Commission authority over hemp industry and delta-8 products. Created 'adult use cannabinoid' definition capturing delta-8, delta-9, and intoxicating isomers, effective July 1, 2022.
Michigan Public Act 56 signed July 13, 2021 and effective October 11, 2021, expanded definition of 'marihuana' to include all THC isomers and synthetic THC, placing delta-8, delta-10, and HHC under cannabis regulatory authority.
Connecticut Senate Bill 1201 restricted most delta-7, delta-8, and delta-10 hemp-derived products to licensed cannabis retailers only, effective July 1, 2021, closing retail market loophole for unregulated intoxicating hemp products.
Nevada Senate Bill 49 redefined THC to include all isomers (delta-8, delta-10) and banned production, distribution, or sale of synthetic cannabinoids without approval from Cannabis Compliance Board. Effective June 4, 2021.
Colorado Department of Public Health and Environment and Marijuana Enforcement Division issued notice prohibiting chemical conversion of naturally occurring cannabinoids from hemp to delta-8 THC, citing lack of safety data on byproducts.
Vermont Agency of Agriculture, Farms, and Markets clarified that delta-8 THC manufacturing from hemp violates state law banning synthetic cannabinoids in hemp products. Prohibition reiterated March 30, 2022.
Washington State Liquor and Cannabis Board issued Policy Statement PS21-01 explicitly prohibiting sale, purchase, and production of delta-8 THC products derived from CBD, citing safety concerns from hemp-derived conversion processes.
7 CFR Part 990 final rule becomes effective, requiring all hemp producers to conduct pre-harvest testing within 30 days of anticipated harvest using DEA-registered labs to determine total THC content via post-decarboxylation analysis.
Delaware Department of Agriculture finalized hemp production regulations on March 11, 2021 prohibiting intoxicating delta-8 products within state, aligning with 2018 Farm Bill hemp definition but maintaining stricter delta-8 ban.
Indiana House of Representatives approved HB 1224 (69-28 vote) on February 17, 2021, reversing the state's 2019 ban on smokable hemp by removing references to 'smokable hemp' from state hemp regulations.
USDA publishes final hemp production rule in Federal Register, incorporating public comments and 2020 lessons; rule effective March 22, 2021, establishing total THC testing via decarboxylation method and formula: Total THC = (THCA × 0.877) + Delta-9 THC.
Utah amended Hemp and Cannabinoid Act during 2021 First Special Session to regulate cannabinoids and impose limits on delta-8 THC concentration in hemp products, classifying artificial cannabinoids as adulterants.
Massachusetts Department of Agricultural Resources clarified in 2021 and again in December 2022 that delta-8 THC derived from hemp is not allowed for commercial sale, as it is synthetically manufactured from CBD isolate.
Kansas HB 2167 created licensing requirements for hemp but formally banned sale of smokable hemp flower, hemp cigars, and CBD flower due to state's strict 0.0% THC requirement for CBD products.
Idaho's HB 126 legalized hemp cultivation but enforces a zero-THC retail standard; manufactured hemp products must test at 0.0% THC, effectively banning all THCA and intoxicating hemp products from retail.
DEA publishes interim final rule conforming DEA regulations to the 2018 Farm Bill's hemp carve-out, clarifying that hemp-derived extracts with delta-9 THC not exceeding 0.3% are decontrolled and no longer require DEA registration or import/export permits.
Louisiana House Bill 843 banned the manufacture and sale of smokable hemp products and CBD-infused foods/beverages, establishing penalties of $300 for first offense and up to $1,000 for second offense. Governor John Bel Edwards signed into law, effective August 1, 2020.
Texas Department of State Health Services implemented rule prohibiting manufacture, processing, distribution, or retail sale of consumable hemp products for smoking, effective August 2020. Ban challenged by Crown Distributing LLC and others.
Following DEA's 2020 interim rule, delta-8 THC products derived from hemp proliferate in the market in gummies, drinks, and other formats; products exploit the 0.3% delta-9 THC limit to bypass controls on other psychoactive cannabinoids.
FDA issues warning letters to CBD manufacturers making therapeutic claims (treating pain, anxiety, COVID-19, etc.) in violation of FD&C Act sections 505(a) and 301(d), treating CBD products as unapproved new drugs lacking FDA approval for human consumption.
Following October 2019 interim rule, USDA begins approving state and tribal hemp production plans; South Carolina, West Virginia, and tribal nations become first approved jurisdictions, establishing the framework for regulated commercial hemp production.
USDA publishes interim final rule (7 CFR Part 990) with detailed requirements for hemp production plans, testing protocols, recordkeeping, and oversight procedures for states and tribes; comment period closes December 30, 2019.
Dr. Amy Abernethy, FDA Principal Deputy Commissioner, testifies before Senate Committee on Agriculture noting 0.3% delta-9 THC carve-out for hemp requires FDA to establish new regulatory framework; FDA commits to expedited pathway rather than 3-5 year delay.
FDA announces that dietary supplement and food frameworks cannot accommodate CBD and commits to developing a new regulatory pathway; public hearing held in June 2019 with comment period closing July 16, 2019.
FDA convenes public hearing to gather scientific information on cannabis and cannabis-derived products; hearing transcript and presentations establish agency's need for better data on CBD safety, efficacy, and manufacturing standards.
Nebraska Governor Pete Ricketts signed LB657 in 2019 legalizing hemp and allowing smokable hemp on private property only, with 0.3% THC limit. Policy remained effective through 2021-2022.
New Hampshire HB 459 (2019) legalized all hemp derivatives and isomers except delta-9 THC, effectively legalizing delta-8 during 2021-2022 period until HB 611 (2023) introduced stricter THC isomer limits.
President Trump signs P.L. 115-334, the Agriculture Improvement Act of 2018, which removes hemp from the Controlled Substances Act and legalizes cultivation nationwide for those meeting the 0.3% delta-9 THC dry-weight threshold.
President Donald Trump signs 2018 Farm Bill, making hemp-derived CBD federally legal and establishing USDA regulatory framework for state hemp programs.
U.S. House passes 2018 Farm Bill (369–47 vote); hemp federally legalized as cannabis with <0.3% THC, allowing states to regulate hemp cultivation and sales.
U.S. Senate passes 2018 Farm Bill (87–13 vote) containing hemp legalization language from McConnell's Hemp Farming Act, removing hemp from controlled substances list.
Michigan voters approve Proposal 1 (56% approval) legalizing adult-use cannabis; allows possession of 2.5 oz and home cultivation of 12 plants; establishes 10% excise tax.
DEA formally places FDA-approved Epidiolex in Schedule V of the Controlled Substances Act, the least restrictive CSA category; applies only to FDA-approved CBD drugs with ≤0.1% THC.
FDA approves Epidiolex oral solution, the first FDA-approved drug containing purified cannabis-derived cannabidiol (CBD), for treatment of seizures in Lennox-Gastaut and Dravet syndromes.
Governor Phil Scott allows H.511 (Act 86) to become law without signature; Vermont becomes first state to legalize recreational cannabis through legislature rather than ballot initiative. Effective July 1, 2018.
U.S. Attorney General Jeff Sessions rescinds the Cole Memorandum, directing U.S. attorneys to use full prosecutorial discretion on federal marijuana offenses regardless of state legality.
California begins commercial adult-use cannabis sales on January 1, 2018; approximately 65 licensed retailers operate statewide including locations in Oakland, Berkeley, and Sebastopol; 15% excise tax applies.
California voters pass Proposition 64 (57.1% approval) legalizing adult-use cannabis; adults 21+ may possess 1 oz and grow 6 plants; retail sales begin January 1, 2018.
Nevada voters approve Question 2 legalizing recreational cannabis for adults 21+ with 15% excise tax; revenue dedicated to enforcement and schools.
Massachusetts voters pass Question 4 (53.59% approval) legalizing adult-use cannabis; establishes regulatory framework and taxation system.
Maine voters approve Question 1 legalizing recreational cannabis; establishes 10% tax and regulation through Department of Agriculture with municipal oversight.
Oregon begins legal sales of recreational marijuana through existing medical dispensaries; over 250 dispensaries open on October 1, 2015, generating $10.8 million in sales within 6 days.
Oregon Measure 91 home cultivation and personal possession provisions become effective; adults 21+ may grow 4 plants and possess 1 oz.
Texas legislature enacts Compassionate Use Act authorizing low-THC cannabis for patients with intractable epilepsy; establishes framework for physician recommendation and patient access.
Tennessee legislature passes SB 280, allowing persons to legally possess cannabis oil obtained out-of-state.
Governor Nathan Deal signs law allowing registered patients to legally possess up to 20 fluid ounces of low-THC cannabis oil with physician recommendations.
Recreational cannabis possession and home cultivation become legal in Alaska; adults 21+ may possess 1 oz and 6 plants under the effective law.
Oregon voters pass Measure 91 (56% approval) legalizing recreational cannabis for adults 21+; allows possession of 1 oz and home cultivation of 4 plants.
Alaska voters approve Measure 2 legalizing recreational cannabis; adults 21+ can possess 1 oz and 6 plants. Takes effect February 24, 2015.
Washington, D.C., voters approve Initiative 71 (64.87%) allowing adults 21+ to possess 2 oz and 6 plants, but Congress simultaneously blocks D.C. from establishing retail sales.
Oregon establishes hemp pilot program under §7606 of the 2014 Farm Bill for research purposes.
Top Shelf Cannabis in Bellingham opens as Washington's first licensed recreational retailer at 8 a.m.; sells 1,000 grams to ~1,000 customers on opening day.
Colorado launches industrial hemp pilot program under §7606; Colorado accounts for 97% of 1,866 acres planted nationally that year across four states.
Kentucky Department of Agriculture launches Industrial Hemp Pilot Program under §7606 following 2013 legislative exemption; begins with 33 acres.
Mississippi passes low-THC cannabis law allowing patients with intractable epilepsy to legally possess CBD oil.
South Carolina Legislature passes law exempting patients with certain medical conditions from criminal penalties for using CBD products containing ≤0.9% THC and >15% CBD.
U.S. House votes 219–189 to pass amendment prohibiting DOJ from spending funds to interfere with state medical cannabis laws; first Congressional vote protecting medical cannabis patients.
Tennessee legislature passes SB 2531, allowing certain patients to use low-THC cannabis oil for medical purposes.
Governor Gary Herbert signs HB 105, allowing patients with intractable epilepsy to possess CBD oil with physician recommendation (minimum 15% CBD, maximum 0.3% THC) and authorizing state hemp research pilot.
Financial Crimes Enforcement Network issues guidance on Bank Secrecy Act expectations for marijuana-related businesses, establishing three categories of suspicious activity reporting and customer due diligence protocols.
Agricultural Act of 2014 Section 7606 authorizes institutions of higher education and state departments of agriculture to grow hemp for agricultural research purposes under state law, establishing the first federal legal framework for hemp cultivation since prohibition.
Colorado opens 24 state-licensed recreational cannabis retailers on January 1, 2014; Sean Azzariti makes first legal recreational purchase globally at 3-D Denver Discrete Dispensary.
Deputy Attorney General James M. Cole issues prosecutorial guidance establishing eight federal marijuana enforcement priorities, signaling DOJ forbearance on state-legal cannabis outside those priorities.
CNN chief medical correspondent Dr. Sanjay Gupta releases documentary following five-year-old Charlotte Figi, whose seizures drop from 300/week to 2-3/month via CBD oil, sparking national CBD demand.
Colorado and Washington voters approve recreational cannabis legalization on November 6, 2012 (55% each), the first jurisdictions globally to legalize adult-use marijuana via ballot initiative.
Governor signs Delaware Senate Bill 17, the Delaware Medical Marijuana Act, establishing the state's medical cannabis program. The law takes effect on July 1, 2011.
Arizona voters approve Proposition 203, the Arizona Medical Marijuana Initiative, creating the state's medical cannabis program for patients with qualifying conditions.
After 12 years of congressional obstruction via the Barr Amendment, Washington DC's Initiative 59 (approved by voters in 1998) is finally implemented, allowing the District to begin registering medical cannabis patients.
Outgoing Governor Jon Corzine signs Senate Bill 119, the Compassionate Use Medical Marijuana Act, on his last full day in office, establishing New Jersey's medical cannabis program.
Deputy Attorney General David W. Ogden issues a memorandum directing federal prosecutors to de-emphasize investigation and prosecution of individuals acting in compliance with state medical marijuana laws, signaling a shift in federal enforcement policy.
Michigan voters approve Proposal 1, the Compassionate Care Initiative, with 63% support, allowing the medical use of marijuana for seriously ill patients and establishing the state's medical cannabis program.
Governor Bill Richardson signs Senate Bill 523, the Lynn and Erin Compassionate Use Act, in April 2007, establishing New Mexico's medical marijuana program.
North Dakota Department of Agriculture begins licensing hemp producers, making North Dakota the first state in the nation to issue state licenses for industrial hemp cultivation under a licensing program.
Rhode Island legislature passes the Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act (S0710) in January 2006, establishing the state's medical cannabis program.
Representatives Ron Paul, Pete Stark, Jim McDermott, and Raul Grijalva introduce HR 3037 to amend the Controlled Substances Act and exempt industrial hemp from the definition of marijuana. The bill does not pass but signals congressional interest in hemp legalization.
Supreme Court rules 6-3 in Gonzales v. Raich that Congress may ban cannabis even when states approve it for medicinal purposes, upholding federal Schedule I status over state medical marijuana laws.
Montana voters approve Initiative I-148 with nearly 62% support, allowing production, possession, and use of marijuana by patients with debilitating medical conditions.
Vermont lawmakers approve Senate Bill 76, legalizing medical marijuana for patients with serious conditions. Governor James Douglas allows the bill to become law without signing on May 19, 2004.
The Ninth Circuit Court of Appeals rules unanimously in favor of Hemp Industries Association, holding that the DEA cannot regulate naturally-occurring THC in hemp and that non-psychoactive hemp is not Schedule I marijuana. The DEA declines to appeal.
Governor Gray Davis signs Senate Bill 420, clarifying and implementing Proposition 215 by establishing ID cards for patients, protecting cooperatives and collectives, and expanding safe harbor provisions.
Ninth Circuit Court of Appeals rules in Conant v. Walters that the DEA cannot revoke physicians' licenses for recommending medical marijuana, protecting doctors' First Amendment rights to communicate with patients about cannabis.
Hemp Industries Association files federal lawsuit challenging DEA regulations that ban hemp-derived products with only trace THC levels, seeking to distinguish legal hemp from prohibited marijuana.
Colorado voters approve Amendment 20 with 54% support, becoming the sixth state to legalize medical marijuana and the first to do so in a single general election alongside Nevada and Hawaii.
Nevada voters approve Question 9 as an initiated constitutional amendment, legalizing medical marijuana and joining Colorado in the November 2000 wave.
Governor Ben Cayetano signs Senate Bill 862, establishing the Hawaii Medical Marijuana Act and making Hawaii the first state to legalize medical marijuana legislatively rather than by ballot initiative. Takes effect in 2001.
Maine voters approve Question 2 to legalize medical marijuana for patients with specified debilitating conditions, establishing Maine as the fourth state to adopt medical marijuana.
Alaska voters approve Measure 8, a medical marijuana ballot measure, with 58.67% support. The law takes effect on March 4, 1999, following California's pioneering Prop 215.
Oregon voters approve Measure 67, legalizing medical marijuana use and possession for patients with qualifying conditions, joining Alaska on the same Election Day.
Washington state voters approve Initiative 692 with 59% support, permitting patients with debilitating conditions to use medical marijuana, extending the 1998 medical marijuana wave to the Pacific Northwest.
District of Columbia voters overwhelmingly approve Initiative 59 with 69% support to legalize medical marijuana. Implementation is blocked by Congress's Barr Amendment until 2009.
California voters approve Proposition 215 with 56% support, permitting physicians to recommend cannabis to patients with serious illnesses. This is the first state medical marijuana ballot initiative to pass, opening the medical marijuana era nationwide.
DEA Chief Administrative Law Judge Francis L. Young issues a 68-page ruling that cannabis should be transferred from Schedule I to Schedule II, stating 'Marijuana has been accepted as capable of relieving distress of great numbers of very ill people.' DEA Administrator John Lawn rejects the finding in 1994.
Robert Randall files a lawsuit against federal agencies seeking legal access to medical cannabis. Within 48 hours, federal agencies settle out-of-court, establishing the Compassionate Investigational New Drug (IND) program that provides legal cannabis to patients.
Federal Judge James Washington rules in favor of Robert Randall, a glaucoma patient, using the medical necessity defense—the first successful common-law necessity defense for cannabis possession. This landmark case launches the medical cannabis movement.
The National Organization for the Reform of Marijuana Laws (NORML) files the first-ever administrative petition to move cannabis from Schedule I to Schedule V or remove it entirely. The Director refuses to accept the petition on September 1, 1972.
The National Commission on Marihuana and Drug Abuse, chaired by former Pennsylvania Governor Raymond P. Shafer, issues 'Marijuana: A Signal of Misunderstanding,' recommending decriminalization and ending prohibition. President Nixon ignores the report.
President Richard Nixon signs the Controlled Substances Act, establishing Schedule I classification for cannabis and hemp without distinction, prohibiting all uses and research nationally for decades.
President Franklin D. Roosevelt signs the Marihuana Tax Act, the first federal anti-marijuana law, imposing a prohibitive tax on cannabis cultivation, possession, and sale nationwide.